What is it about?
Hepatocellular carcinoma (HCC) is a major concern and is responsible for leading deaths worldwide, and several drugs and nanocarriers are under rigorous study to target HCC. This chapter briefly describes drugs used for HCC therapy, their current status in clinical phase trials, and their shortcomings when used in free form. Further, the various nanocarriers developed to deliver the drugs efficiently at the tumor site to reduce the side effects and enhance therapeutic efficiency and their status in phase trials have been discussed. Overall, this chapter gives a detailed view of different strategies to develop nanocarriers and their foreseen benefits in HCC therapy.
Featured Image
Why is it important?
In this chapter, we focused on providing a descriptive view on the advantages and disadvantages of drugs when used in free form and nanoformulations to target HCC. Further, a quick view of their outcomes in clinical phase trials and foreseen approaches to develop better and more efficient nanocarriers to reduce side effects is included.
Perspectives
Writing this book chapter allowed me to understand the vital role of nanocarriers in treating hepatocellular carcinoma. Specifically, knowing the clinical status of these nanocarriers assisted me in thinking and developing a better strategy to fabricate the drug delivery systems.
SURESH AJMEERA
Read the Original
This page is a summary of: Nanoformulations to Limit Challenges of Conventional Therapy Against Hepatocellular Carcinoma – An Overview, March 2022, Bentham Science Publishers,
DOI: 10.2174/9789815039740122010006.
You can read the full text:
Resources
Contributors
The following have contributed to this page
